Ian A. Parish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ian A. Parish has a total of 533 co-authors. Here are the top co-authors by number of shared publications:
- Jane Oliaro
The Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia
12 shared publications - Paul Andrew Beavis
Peter MacCallum Cancer Centre
12 shared publications - Christopher C. Goodnow
Garvan Institute of Medical Research, Sydney, Australia
9 shared publications - Isabelle Munoz
Peter MacCallum Cancer Centre
9 shared publications Kelly M. Ramsbottom
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
9 shared publications- Kevin Sek
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia
9 shared publications
Latest Publications
- 11 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (12)
Early fate bias and TCR sequence shape CD8+ T cell differentiation and expansion
When a naive CD8+ T cell encounters an antigen, it proliferates into descendants with identical T cell receptors (TCRs), termed clones. Whether their differentiation toward effector or memory fates is stochastic or TCR-dependent has remained unclear, largely because the vast diversity of TCRs makes individual clones difficult to trace over time. Using single-cell RNA and TCR sequencing in acute LCMV Armstrong infection, we found that clonal distributions in blood reflect those in lymphoid organs, enabling nonlethal longitudinal tracking of clonal evolution. Tracing hundreds of clones, we found that memory clonal distribution is surprisingly uncoupled from early dominance; instead, early central memory precursor frequency predicts memory dominance. Leveraging convergent recombination, we identified clones with identical CDR3 amino acid sequences in mice and found that these natural biological replicates were more likely than chance to adopt similar fates, although substantial clone-to-clone variation remained. Applying the TCR distance algorithm, we further identified dominant motifs associated with enhanced expansion and effector-biased transcriptional programs, extending the TCR’s role in shaping clonal differentiation.
- 11 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (12)
Early fate bias and TCR sequence shape CD8+ T cell differentiation and expansion
When a naive CD8+ T cell encounters an antigen, it proliferates into descendants with identical T cell receptors (TCRs), termed clones. Whether their differentiation toward effector or memory fates is stochastic or TCR-dependent has remained unclear, largely because the vast diversity of TCRs makes individual clones difficult to trace over time. Using single-cell RNA and TCR sequencing in acute LCMV Armstrong infection, we found that clonal distributions in blood reflect those in lymphoid organs, enabling nonlethal longitudinal tracking of clonal evolution. Tracing hundreds of clones, we found that memory clonal distribution is surprisingly uncoupled from early dominance; instead, early central memory precursor frequency predicts memory dominance. Leveraging convergent recombination, we identified clones with identical CDR3 amino acid sequences in mice and found that these natural biological replicates were more likely than chance to adopt similar fates, although substantial clone-to-clone variation remained. Applying the TCR distance algorithm, we further identified dominant motifs associated with enhanced expansion and effector-biased transcriptional programs, extending the TCR’s role in shaping clonal differentiation.
- Open Access
ClustoCell reveals cell states and their markers from single-cell transcriptomes
Accurate identification of cell types and states is essential for reliable single-cell RNA-sequencing analyses, yet current methods remain sensitive to continuous biological states, data preprocessing choices, and reference selection. Here we present ClustoCell, a reference-free method that resolves cell identity using within-cell transcriptional architecture. By stratifying gene expression of each cell into high and medium tiers, ClustoCell constructs cell-cell similarity graphs that prioritize intrinsic expression structure over global variance. Across 450 datasets spanning over 24 million cells, ClustoCell recovered expert annotations with high concordance (92%). Benchmarked against state-of-the-art methods, ClustoCell identifies more stable and coherent cell types and states, avoids excessive partitioning of closely related cells, and improves the identification of cell type-specific markers. From transcriptional structure alone, ClustoCell resolves rare and transitional cell states, distinguishes malignant from non-malignant cells, and refines expert cell annotations. Applied to immunotherapy datasets, ClustoCell uncovered coordinated pre-treatment immune circuits linking T cell states to PD-1 responsiveness in a tumour-type-specific manner. ClustoCell provides an interpretable and scalable foundation for single-cell analysis and translational profiling.
Open AccessClustoCell reveals cell states and their markers from single-cell transcriptomes
Accurate identification of cell types and states is essential for reliable single-cell RNA-sequencing analyses, yet current methods remain sensitive to continuous biological states, data preprocessing choices, and reference selection. Here we present ClustoCell, a reference-free method that resolves cell identity using within-cell transcriptional architecture. By stratifying gene expression of each cell into high and medium tiers, ClustoCell constructs cell-cell similarity graphs that prioritize intrinsic expression structure over global variance. Across 450 datasets spanning over 24 million cells, ClustoCell recovered expert annotations with high concordance (92%). Benchmarked against state-of-the-art methods, ClustoCell identifies more stable and coherent cell types and states, avoids excessive partitioning of closely related cells, and improves the identification of cell type-specific markers. From transcriptional structure alone, ClustoCell resolves rare and transitional cell states, distinguishes malignant from non-malignant cells, and refines expert cell annotations. Applied to immunotherapy datasets, ClustoCell uncovered coordinated pre-treatment immune circuits linking T cell states to PD-1 responsiveness in a tumour-type-specific manner. ClustoCell provides an interpretable and scalable foundation for single-cell analysis and translational profiling.
- 10 August 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (9) , 1224-1225
A high-fibre diet-derived microbial polyphenol metabolite boosts T-cell stemness in cancer immunotherapy
- 10 August 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (9) , 1224-1225
A high-fibre diet-derived microbial polyphenol metabolite boosts T-cell stemness in cancer immunotherapy
- Open Access
- 17 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion
CD8+ T cell exhaustion is a regulatory state triggered by chronic antigen stimulation in both cancer and persistent infection. The less differentiated stem-like sub-populations of exhausted T cells have been heavily studied given their importance to the efficacy of current immunotherapies. While the transcription factor TCF1 is both necessary and sufficient for formation and maintenance of these stem-like populations, it remains unclear whether TCF1 can actively de-differentiate more terminally exhausted subsets back into a stem-like state. To address this question, here we utilize and optimize a high efficiency CRISPR knock-in methodology, compatible with mouse in vivo exhaustion models, to engineer T cells that either constitutively over-express TCF1, or conditionally over-express TCF1 following differentiation of the cells into a CX3CR1+ intermediate-exhausted state. Strikingly, we find that only constitutive, and not conditional, TCF1 over-expression can increase the size of the stem-like T cell pool. Thus, while TCF1 can slow stem-like T cell differentiation, it is insufficient to revert more differentiated cells back into a stem-like state.
- 17 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessHigh efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion
CD8+ T cell exhaustion is a regulatory state triggered by chronic antigen stimulation in both cancer and persistent infection. The less differentiated stem-like sub-populations of exhausted T cells have been heavily studied given their importance to the efficacy of current immunotherapies. While the transcription factor TCF1 is both necessary and sufficient for formation and maintenance of these stem-like populations, it remains unclear whether TCF1 can actively de-differentiate more terminally exhausted subsets back into a stem-like state. To address this question, here we utilize and optimize a high efficiency CRISPR knock-in methodology, compatible with mouse in vivo exhaustion models, to engineer T cells that either constitutively over-express TCF1, or conditionally over-express TCF1 following differentiation of the cells into a CX3CR1+ intermediate-exhausted state. Strikingly, we find that only constitutive, and not conditional, TCF1 over-expression can increase the size of the stem-like T cell pool. Thus, while TCF1 can slow stem-like T cell differentiation, it is insufficient to revert more differentiated cells back into a stem-like state.
- Open Access
- 10 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 530-542
Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes
Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation status controls response, with less differentiated cells having an enhanced capacity to proliferate after ICB. Given that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted T cells (TPEX), we hypothesized that expansion of cDC1s with Flt3L could enhance responses to ICB. Here we show that treatment with Fms-related tyrosine kinase 3 ligand (Flt3L) expands CD62L+SLAMF6+CD8+ T cells in the tumor through a mechanism that requires XCR1+ dendritic cells to traffic to the tumor-draining lymph node. The combination of Flt3L and anti-CTLA-4 enhanced therapeutic responses. Combination therapy is associated with the emergence of a CD8+ T cell subset characterized by the expression of Il21r and oligoclonal expansion of CD8+ T cells within tumors through a mechanism that is dependent on lymph node egress.
- 10 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 530-542
Open AccessFlt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes
Immune checkpoint blockade (ICB) evokes antitumor immunity through the reinvigoration of T cell responses. T cell differentiation status controls response, with less differentiated cells having an enhanced capacity to proliferate after ICB. Given that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted T cells (TPEX), we hypothesized that expansion of cDC1s with Flt3L could enhance responses to ICB. Here we show that treatment with Fms-related tyrosine kinase 3 ligand (Flt3L) expands CD62L+SLAMF6+CD8+ T cells in the tumor through a mechanism that requires XCR1+ dendritic cells to traffic to the tumor-draining lymph node. The combination of Flt3L and anti-CTLA-4 enhanced therapeutic responses. Combination therapy is associated with the emergence of a CD8+ T cell subset characterized by the expression of Il21r and oligoclonal expansion of CD8+ T cells within tumors through a mechanism that is dependent on lymph node egress.
- Open Access
- 16 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 436-451
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses are maintained by quiescent stem-like/memory cells dependent upon the transcription factor BACH2. Here we show that quantitative control of BACH2 dosage regulates differentiation along the continuum of stem and effector CD8⁺ T cell states, enabling engineering of synthetic states with persistent antitumor activity. While conventional high-level overexpression of BACH2 enforces quiescence and hinders tumor control, low-dose BACH2 expression promotes persistence without compromising effector function, enhancing anticancer efficacy. Mechanistically, low-dose BACH2 partially attenuates Jun occupancy at highly AP-1-dependent genes, restraining terminal differentiation while preserving effector programs. Similarly, dose optimization enables effective deployment of quiescence factor FOXO1. Thus, quantitative control of gene payloads yields qualitative effects on outcome with implications for quiescence factor deployment in cell therapy.
- 16 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 436-451
Open AccessFine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses are maintained by quiescent stem-like/memory cells dependent upon the transcription factor BACH2. Here we show that quantitative control of BACH2 dosage regulates differentiation along the continuum of stem and effector CD8⁺ T cell states, enabling engineering of synthetic states with persistent antitumor activity. While conventional high-level overexpression of BACH2 enforces quiescence and hinders tumor control, low-dose BACH2 expression promotes persistence without compromising effector function, enhancing anticancer efficacy. Mechanistically, low-dose BACH2 partially attenuates Jun occupancy at highly AP-1-dependent genes, restraining terminal differentiation while preserving effector programs. Similarly, dose optimization enables effective deployment of quiescence factor FOXO1. Thus, quantitative control of gene payloads yields qualitative effects on outcome with implications for quiescence factor deployment in cell therapy.
- Open Access
- 3 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor. To overcome this, Chimeric Antigen Receptor T cells are engineered to express A1 receptor, a receptor that signals inversely to A2A receptor. Using murine and human Chimeric Antigen Receptor T cells, constitutive A1 receptor overexpression significantly enhances Chimeric Antigen Receptor T cell effector function albeit at the expense of Chimeric Antigen Receptor T cell persistence. Through a CRISPR/Cas9 homology directed repair “knock-in” approach we demonstrate that Chimeric Antigen Receptor T cells engineered to express A1 receptor in a tumor-localized manner, enhances anti-tumor therapeutic efficacy. This is dependent on the transcription factor IRF8 and is transcriptionally unique when compared to A2A receptor deletion. This data provides a novel approach for enhancing Chimeric Antigen Receptor T cell efficacy in solid tumors and provides proof of principle for site-directed expression of factors that promote effector T cell differentiation.
- 3 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessTumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor. To overcome this, Chimeric Antigen Receptor T cells are engineered to express A1 receptor, a receptor that signals inversely to A2A receptor. Using murine and human Chimeric Antigen Receptor T cells, constitutive A1 receptor overexpression significantly enhances Chimeric Antigen Receptor T cell effector function albeit at the expense of Chimeric Antigen Receptor T cell persistence. Through a CRISPR/Cas9 homology directed repair “knock-in” approach we demonstrate that Chimeric Antigen Receptor T cells engineered to express A1 receptor in a tumor-localized manner, enhances anti-tumor therapeutic efficacy. This is dependent on the transcription factor IRF8 and is transcriptionally unique when compared to A2A receptor deletion. This data provides a novel approach for enhancing Chimeric Antigen Receptor T cell efficacy in solid tumors and provides proof of principle for site-directed expression of factors that promote effector T cell differentiation.
- Top Cited PapersOpen Access
- 2 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8075) , 241-251
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1,2,3. To overcome these barriers, ‘armoured’ CAR T cells, which secrete proinflammatory cytokines, have been developed4. However, their clinical application has been limited because of toxicity related to peripheral expression of the armouring transgene5. Here, we have developed a CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumour-localized manner. By screening endogenous genes with tumour-restricted expression, we have identified the NR4A2 and RGS16 promoters as promising candidates to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumour site, leading to enhanced antitumour efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This effect was concomitant with improved CAR T cell polyfunctionality, activation of endogenous antitumour immunity and a favourable safety profile, and was applicable in CAR T cells from patients.
- 2 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8075) , 241-251
Top Cited PapersOpen AccessRewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1,2,3. To overcome these barriers, ‘armoured’ CAR T cells, which secrete proinflammatory cytokines, have been developed4. However, their clinical application has been limited because of toxicity related to peripheral expression of the armouring transgene5. Here, we have developed a CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumour-localized manner. By screening endogenous genes with tumour-restricted expression, we have identified the NR4A2 and RGS16 promoters as promising candidates to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumour site, leading to enhanced antitumour efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This effect was concomitant with improved CAR T cell polyfunctionality, activation of endogenous antitumour immunity and a favourable safety profile, and was applicable in CAR T cells from patients.
- Open Access
- 6 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Spatial and stoichiometric in situ analysis of biomolecular oligomerization at single-protein resolution
Latest advances in super-resolution microscopy allow the study of subcellular features at the level of single proteins, which could lead to discoveries in fundamental biological processes, specifically in cell signaling mediated by membrane receptors. Despite these advances, accurately extracting quantitative information on molecular arrangements of proteins at the 1–20 nm scale through rigorous image analysis remains a significant challenge. Here, we present SPINNA (Single-Protein Investigation via Nearest-Neighbor Analysis): an analysis framework that compares nearest-neighbor distances from experimental single-protein position data with those obtained from realistic simulations based on a user-defined model of protein oligomerization states. We demonstrate SPINNA in silico, in vitro, and in cells. In particular, we quantitatively assess the oligomerization of the epidermal growth factor receptor (EGFR) upon EGF treatment and investigate the dimerization of CD80 and PD-L1, key surface ligands involved in immune cell signaling. Importantly, we offer an open-source Python implementation and a GUI to facilitate SPINNA’s widespread use in the scientific community.
- 6 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Open AccessSpatial and stoichiometric in situ analysis of biomolecular oligomerization at single-protein resolution
Latest advances in super-resolution microscopy allow the study of subcellular features at the level of single proteins, which could lead to discoveries in fundamental biological processes, specifically in cell signaling mediated by membrane receptors. Despite these advances, accurately extracting quantitative information on molecular arrangements of proteins at the 1–20 nm scale through rigorous image analysis remains a significant challenge. Here, we present SPINNA (Single-Protein Investigation via Nearest-Neighbor Analysis): an analysis framework that compares nearest-neighbor distances from experimental single-protein position data with those obtained from realistic simulations based on a user-defined model of protein oligomerization states. We demonstrate SPINNA in silico, in vitro, and in cells. In particular, we quantitatively assess the oligomerization of the epidermal growth factor receptor (EGFR) upon EGF treatment and investigate the dimerization of CD80 and PD-L1, key surface ligands involved in immune cell signaling. Importantly, we offer an open-source Python implementation and a GUI to facilitate SPINNA’s widespread use in the scientific community.